Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: Establishment of a new transplantable in vivo model for malignant glioma

Journal of Neurosurgery

Volumn 106, Issue 4, 2007, Pages 652-659

  Smilowitz, Henry M ^a   Weissenberger, Jakob ^b,e   Weis, Joachim ^b,c   Brown, Judith D ^d   O'Neill, Rachel J ^d   Laissue, Jean A ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Glioma; Immunogenicity; Syngeneic mouse model; Transplantation; v src transgene

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; GLIAL FIBRILLARY ACIDIC PROTEIN; JANUS KINASE; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; GLIOMA; GLIOMA CELL; HISTOPATHOLOGY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENES, SRC; GLIOMA; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS;

EID: 34047198197     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2007.106.4.652     Document Type: Article

References (34)

1. Amalfitano G, Chatel M, Paquis P, Michiels JF: Fluorescence in situ hybridization study of aneuploidy of chromosomes 7, 10, X, and Y in primary and secondary glioblastomas. Cancer Genet Cytogenet 116:6-9, 2000
2. Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR, Del Maestro RF: Src regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2:595-605, 2004
3. Band CJ, Mounier C, Posner BI: Epidermal growth factor and insulin-induced deoxyribonucleic acid synthesis in primary rat hepatocytes is phosphatidylinositol 3-kinase dependent and dissociated from protooncogene induction. Endocrinology 140: 5626-5634, 1999
4. Benn P, Perle M: Chromosome staining and banding techniques, in Rooney DE, Czepulkowski BH (eds): Human Cytogenetics: A Practical Approach. New York: Oxford University Press, 1992, pp 91-117
5. Bigner SH, Vogelstein B: Cytogenetics and molecular genetics of malignant gliomas and medullobalstoma. Brain Pathol 1:12-18, 1990
6. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558, 1998
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al: Stat3 as an oncogene. Cell 98:295-303, 1999
8. Frame MC: Src in cancer: deregulation and consequences for cell behavior. Biochem Biophys Acta 1602:114-130, 2002
9. Fung YK, Crittenden LB, Fadly AM, Kung HJ: Tumor induction by direct injection of cloned v-src DNA into chickens. Proc Natl Acad Sci U S A 80:353-357, 1983
10. Gelman IH, Hanafusa H: src-specific immune regression of Rous sarcoma virus-induced tumors. Cancer Res 53:915-920, 1993
11. Holland EC: Mouse models of human cancer as tools in drug development. Cancer Cell 6:197-198, 2004
12. Hosmer DW Jr, Lemeshow S: Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999
13. Kim DH, Mohapatra G, Bollen A, Waldman FM, Feuerstein BG: Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 60:812-819, 1995
14. Lassman AB: Molecular biology of gliomas. Curr Neurol Neurosci Rep 4:228-233, 2004
15. Loeffler S, Fayard B, Weis J, Weissenberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115:202-213, 2005
16. Loeper S, Romeike BF, Heckmann N, Jung V, Henn W, Feiden W, et al: Frequent mitotic errors in tumor cells of genetically microheterogeneous glioblastomas. Cytogenet Cell Genet 94:1-8, 2001
17. Lund CV, Nguyen MTN, Owens GC, Pakchoian AJ, Shaterian A, Kruse CA, et al: Reduced glioma infiltration in Src-deficient mice. J Neurooncol 78:19-29, 2006
18. Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasienti P, Adams J, et al: Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle 5:783-791, 2006
19. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008, 2002
20. Paz K, Socci ND, Van Nimwegen E, Viale A, Darnell JE: Transformation fingerprint: induced STAT3-c, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA. Oncogene 23:8455-8463, 2004
21. Pohl U, Wick W, Weissenberger J, Steinbach JP, Dichgans J, Aguzzi A, et al: Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. Int J Oncol 15:829-834, 1999
22. Rao VK, Wangsa D, Robey RW, Huff L, Honjo Y, Hung J, et al: Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoantrone-selected SF295 human glioblastoma cells. Cancer Genet Cytogenet 160:126-133, 2005
23. Romer J, Curran T: Targeting medulloblastoma: Small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 65:4975-4978, 2005
24. Smilowitz HM, Joel DD, Slatkin DN, Micca PL, Nawrocky MM, Youngs K, et al: Long-term immunological memory in the resistance of rats to transplantable intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS cells. J Neurooncol 46:193-203, 2000
25. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, et al: Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 65:5535-5543, 2005
26. Theurillat JP, Hainfellner J, Maddalena A, Weissenberger J, Aguzzi, A: Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am J Pathol 154:581-590, 1999
27. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8:409-422, 2004
28. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R: Stat3 activation by src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552, 1998
29. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, et al: IL-6 is required for glioma development in a mouse model. Oncogene 23:3308-3316, 2004
30. Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A, et al: Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14:2005-2013, 1997
31. Wemmert S, Ketter R, Rahnenfuhrer J, Beerenwinkel N, Strowitzki M, Friden W, et al: Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 7:883-893, 2005
32. Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, Mobley WC, et al: EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell 96:677-687, 1999
33. Wisner TW, England JM, Pan DY, Stoker AW, Halpern MS: Tumor immunity generated in the course of regression of v-src induced sarcomas. J Virol 65:7020-7024, 1991
34. Yu H, Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4:97-105, 2004